1. Inhibition of MCL1 reduces AML in an in vivo murine model.
Inhibition of MCL1 reduces AML in an in vivo murine model. A, NSGS mice were engrafted with MV-4-11 human leukemia cells and were then treated with either vehicle (n = 6) or 10 (n = 5), 25 (n = 5), or 75 (n = 5) mg/kg of VU Peripheral blood, bone marrow (BM), and spleen (SPL) were harvested for tricompartmental chimerism analysis. A nonparametric, unpaired, two-tailed t test was used to calculate significance. B, IHC of femurs and spleen (20×) stained with monoclonal antibody for hCD45 reveal AML cells left within the bone marrow and spleen of experimental mice at each dose level. C, Ratio of spleen to total body weight measurements from above-mentioned experiments. D, Kaplan–Meier analysis. Statistical significance was calculated using log-rank (Mantel–Cox) test (P = 0.001; n = 5 per arm).
Haley E. Ramsey et al. Cancer Discov 2018;8:
©2018 by American Association for Cancer Research